We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+5.79%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$64.7B
AUM Growth
+$5.24B
Cap. Flow
+$2.36B
Cap. Flow %
3.65%
Top 10 Hldgs %
20.54%
Holding
3,821
New
235
Increased
1,962
Reduced
1,317
Closed
186

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$40.1M
2
T icon
AT&T
T
+$28M
3
FTXO icon
First Trust Nasdaq Bank ETF
FTXO
+$24.3M
4
TTE icon
TotalEnergies
TTE
+$23.7M
5
WMT icon
Walmart Inc
WMT
+$22.8M

Sector Composition

Rank Sector Weight
1 Technology 10.68%
2 Financials 9.21%
3 Healthcare 8.48%
4 Industrials 6.92%
5 Consumer Discretionary 5.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WOW
3701
CALL
DELISTED
WideOpenWest
WOW
-11,600
Closed -$5K
WOW
3702
DELISTED
WideOpenWest
WOW
-68,050
Closed -$657K
WPRT
3703
PUT
Westport Fuel Systems
WPRT
$35.7M
-2,500
Closed -$44K
WY icon
3704
CALL
Weyerhaeuser
WY
$18.4B
-23,300
Closed -$3K
XPRO icon
3705
Expro Ltd
XPRO
$1.91B
-3,783
Closed -$177K
PENG
3706
Penguin Solutions Inc
PENG
$2.99B
-20,520
Closed -$327K
INFN
3707
DELISTED
Infinera Corporation Common Stock
INFN
-43,524
Closed -$432K
LUMO
3708
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
-3,447
Closed -$148K
MRO
3709
CALL
DELISTED
Marathon Oil Corporation
MRO
-33,300
Closed -$5K
CHUY
3710
CALL
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
-78,100
Closed -$320K
CHUY
3711
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
-85,495
Closed -$2.63M
TWOU
3712
DELISTED
2U Inc
TWOU
-508
Closed -$1.27M
TTOO
3713
DELISTED
T2 Biosystems, Inc
TTOO
-3
Closed -$100K
APRN
3714
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
-116
Closed -$70K
RAD
3715
CALL
DELISTED
Rite Aid Corporation
RAD
-750
Closed -$1K
DBD
3716
DELISTED
Diebold Nixdorf Incorporated
DBD
-413,977
Closed -$4.95M
ACOR
3717
CALL
DELISTED
Acorda Therapeutics
ACOR
-762
Closed -$251K
BIOC
3718
DELISTED
Biocept, Inc.
BIOC
-3
Closed -$5K
VNTR
3719
DELISTED
Venator Materials PLC
VNTR
-10,884
Closed -$178K
BSMX
3720
DELISTED
Banco Santander México, S, A., Institución de Banca Múltiple, Grupo Financiero Santander México
BSMX
-349,428
Closed -$2.34M
PLXP
3721
DELISTED
PLx Pharma Inc. Common Stock
PLXP
-10,448
Closed -$41K
CAJ
3722
DELISTED
Canon, Inc.
CAJ
-24,676
Closed -$807K
LCI
3723
DELISTED
Lannett Company, Inc.
LCI
-9,560
Closed -$520K
ZNH
3724
DELISTED
China Southern Airlines Company Limited
ZNH
-5,456
Closed -$216K
BNFT
3725
CALL
DELISTED
Benefitfocus, Inc.
BNFT
-10,600
Closed -$52K

Similar funds

Raymond James & Associates's Q3 2018 Portfolio in Review

As of Q3 2018, Raymond James & Associates held 3,821 positions worth $64.7B, up 8.8% from $59.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates deployed $2.36B of net new capital in Q3 2018, opening 235 new positions and adding to 1,962 existing holdings. Its largest new stake was State Street Communication Services Select Sector SPDR ETF: 365,478 shares worth $17.9M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 10% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Sanofi, an estimated $40.1M trimmed.

  • Raymond James & Associates's largest Q3 2018 buy was State Street Communication Services Select Sector SPDR ETF: 365,478 shares worth $17.9M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q3 2018, an estimated $155M increase.
  • Raymond James & Associates's biggest Q3 2018 reduction was Sanofi, cutting an estimated $40.1M.
  • Raymond James & Associates fully exited Abaxis Inc in Q3 2018, selling an estimated $10.5M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $64.7B portfolio in Q3 2018.
  • Raymond James & Associates opened 235 new positions and closed 186 in Q3 2018.
  • Raymond James & Associates's portfolio value rose 8.8% quarter-over-quarter to $64.7B.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.